Sir John Bell | |
---|---|
Born | John Irving Bell 1 July 1952 Edmonton, Alberta, Canada |
Citizenship | Canadian, British |
Education | |
Scientific career | |
Fields | Immunology, genetics |
Website | https://www.medsci.ox.ac.uk/divisional-services/staff/regius |
Sir John Irving Bell (born 1 July 1952 [1] ) is a Canadian-British immunologist and geneticist. [2] From 2006 to 2011, he was President of the United Kingdom's Academy of Medical Sciences, and since 2002 he has held the Regius Chair of Medicine at the University of Oxford. [3] He was since 2006 Chairman of the Office for Strategic Coordination of Health Research (OSCHR) but in 2020 became a normal member. [4] Bell was selected to the Vaccine Taskforce sometime before 1 July 2020. [5] Bell is also on the board of directors of the SOE quango Genomics England.
Bell was born in Edmonton, Alberta, where his parents worked in haematology and pharmacy. He attended Ridley College in St. Catharines, Ontario. He graduated from the University of Alberta in 1975, and then studied medicine on a Rhodes Scholarship at Magdalen College, Oxford. [3] In 1978, he rowed in the Oxford University Lightweight Rowing Club Blue Boat which raced against the University of Cambridge. [6]
In 1982, despite lacking advanced scientific qualifications, he took up a position as Clinical Fellow in Immunology with Hugh McDevitt at Stanford University, where he worked on histocompatibility antigens and autoimmune disease. [3] [7] [8]
In 1987, Bell returned to Oxford as a Wellcome Trust Senior Clinical Fellow, and joined the Institute of Molecular Medicine, founded by David Weatherall. In 1992, he succeeded Weatherall as the Nuffield Professor of Clinical Medicine and, in 2002, became the Regius Professor of Medicine at Oxford, also after Weatherall. In 1994, Bell was one of the founders of the Wellcome Trust Centre for Human Genetics at Oxford University. [3] [7] He is an emeritus fellow of Magdalen College, Oxford. [9] Bell is also the senior member of the Oxford University Women's Boat Club Executive Committee [10] and is a member of the Governing Body of Christ Church, Oxford. [11] He sat on the Council of the Medical Research Council between 1998 and 2003. [12] [13] Since 2011, Bell has been one of two Life Sciences Champions for the UK.
Bell has been a non-executive director of Roche since 2001. [14] A BMJ campaign to make the results of unpublished studies on the anti-influenza drug oseltamivir (Tamiflu) available to researchers led to the journal's editor Fiona Godlee urging Bell "as an internationally respected scientist and clinician and a leader of clinical research in the United Kingdom, to bring your influence to bear on your colleagues on Roche's board." [15] Roche subsequently agreed to a wide policy of data transparency in clinical trials. Matthew Thompson and Carl Heneghan wrote in a letter to the journal "...according to Roche's 2011 financial report, John Bell received 390 000 Swiss Francs (£260 450; €322 450; $420 000) last year for his role on the board of directors. What do Roche and its shareholders expect for this level of involvement and remuneration?" [16] [17] The House of Commons Science and Technology Committee report on the subject broadly supported the release of more clinical trial data but urged caution on public release of individual patient data.
Bell serves on the Genentech Board in San Francisco, and formerly served on the scientific advisory board of AstraZeneca (1997–2000). [7] He was the founding director of three biotechnology companies, [3] [7] including Oxagen, Avidex, and Powderject and is also on the Board of Atopix.
His charity positions include chairing the board of trustees of the Oxford Health Alliance [8] and the science committee of the UK Biobank. [18] He chairs the Global Health Scientific advisory board of the Bill & Melinda Gates Foundation, he is a Trustee of the Rhodes Trust, he sits on the award jury of the Gairdner Foundation, he is a non-executive member of Genomics England, and he is a member of Cancer Research UK. He has advised governments and foundations in Singapore, France, Canada, Sweden, Finland, and Alberta on biomedical research. He is on the Jenner Institute Board and the Gray Institute Board. He is on the advisory Board for the McGill Genomics Institute and the Montreal Neurological Institute, and chairs the advisory board for the Oak Foundation and the Robertson Foundation. He attended the 2013 Bilderberg Conference. [19]
A 2021 feature article by freelance journalist Paul D Thacker in the BMJ stated: "The government and Oxford University's failure to be open about Bell's financial ties make[s] it impossible for the public to know what, if any, interests the professor has when influencing key decisions about which of the many covid-19 tests the UK should purchase." [20]
Bell's research has contributed immensely to science[ citation needed ]: he identified genes involved in susceptibility to diabetes mellitus type 1 and rheumatoid arthritis and multiple sclerosis. His work has been important in elucidating the interactions on the surface of the T cell involved in immune activation. He has also worked on the biomedical applications of high-throughput genomic technologies, including structural genomics and ENU mutagenesis. [7] He has been directly involved in applying genetics in a clinical settings and helped developed the 100,000 genome project for Genomics England.
Bell was elected a Fellow of the Academy of Medical Sciences (FMedSci) in 1998. [21] He was awarded an honorary D.Sc. degree by the University of Alberta in 2003. [22] Bell was President of the Academy of Medical Sciences from 2006 to 2011. [3] [23] In 2008, he was elected a Fellow of the Royal Society (FRS). [24] He was appointed an Honorary Fellow of the Royal Academy of Engineering (HonFREng) [25] in 2009, [26] and was knighted in the 2008 New Year Honours for services to medicine. [27] He has received honorary degrees from the Universities of York, Warwick, Glasgow, Dundee, Imperial College, King's College London and University of Toronto (2014).
He was appointed Knight Grand Cross of the Order of the British Empire (GBE) in the 2015 New Year Honours for services to medicine, medical research and the life science industry. [28] [29] In addition to Sir Charles Gordon and Sir Edward Beatty, Bell is one of the few Canadians to be admitted to the highest class in this order. He was appointed Member of the Order of the Companions of Honour (CH) in the 2023 Birthday Honours for services to medicine, medical research, the life science industry and public health. [30]
Magdalen College is a constituent college of the University of Oxford. It was founded in 1458 by Bishop of Winchester William of Waynflete. It is one of the wealthiest Oxford colleges, as of 2022, and one of the strongest academically, setting the record for the highest Norrington Score in 2010 and topping the table twice since then. It is home to several of the university's distinguished chairs, including the Agnelli-Serena Professorship, the Sherardian Professorship, and the four Waynflete Professorships.
Sir Kenneth Charles Calman is a Scottish doctor and academic who formerly worked as a surgeon, oncologist and cancer researcher and held the position of Chief Medical Officer of Scotland, and then England. He was Warden and Vice-Chancellor of Durham University from 1998 to 2006 before becoming Chancellor of the University of Glasgow. He held the position of Chair of the National Cancer Research Institute from 2008 until 2011. From 2008 to 2009, he was convener of the Calman Commission on Scottish devolution.
Sir Michael Gideon Marmot is Professor of Epidemiology and Public Health at University College London. He is currently the Director of The UCL Institute of Health Equity. Marmot has led research groups on health inequalities for over thirty years, working for various international and governmental bodies. In 2023, he was elected to the American Philosophical Society.
Sir David John Weatherall, was a British physician and researcher in molecular genetics, haematology, pathology and clinical medicine.
Ara Warkes Darzi, Baron Darzi of Denham is an Armenian-British surgeon, academic, and politician.
The British Pharmacological Society is the primary UK learned society for pharmacologists, concerned with research into drugs and the ways in which they work. Members work in academia, industry, regulatory agencies, and the health services, and many are medically qualified. The Society covers the whole spectrum of pharmacology, including laboratory, clinical, and toxicological aspects.
John Michael Newsom-Davis was a neurologist who played an important role in the discovery of the causes of, and treatments for, Myasthenia gravis, and of other diseases of the nerve-muscle junction, notably Lambert–Eaton myasthenic syndrome and acquired neuromyotonia. Regarded as "one of the most distinguished clinical neurologists and medical scientists of his generation," he died in a car accident in Adjud, Romania, having visited a neurological clinic in Bucharest earlier the same day.
Sir John Stewart Savill, FRS, FMedSci is the Chief Executive of the Medical Research Council (MRC) in the UK and the Head of the College of Medicine and Veterinary Medicine and a Vice Principal of the University of Edinburgh.
Sir Liam Joseph Donaldson is a British physician. He was formerly the Chief Medical Officer for England, being the 15th occupant of the post since it was established in 1855. As such, he was principal advisor to the United Kingdom Government on health matters and one of the most senior officials in the National Health Service (NHS).
Sir Rory Edwards Collins FMedSci FRS is a British physician who is Professor of Medicine and Epidemiology at the Clinical Trial Service Unit within the University of Oxford, the head of the Nuffield Department of Population Health and a Fellow of Green Templeton College, Oxford. His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer, while also being closely involved in developing approaches to the combination of results from related studies ("meta-analyses"). Since September 2005, he has been the Principal Investigator and Chief Executive of the UK Biobank, a prospective study of 500,000 British people aged 40–69 at recruitment.
Alastair Buchan is a British neurologist and researcher in stroke medicine. His main research interest is how to make neuroprotection a reality in the clinic. From October 2008 until January 2017, he served as the Dean of Medicine and the Head of the Medical Sciences Division, University of Oxford. He currently holds the Chair of Stroke Research at the University of Oxford.
Christopher Carl Goodnow is an immunology researcher and the current executive director of the Garvan Institute of Medical Research. He holds the Bill and Patricia Ritchie Foundation Chair and is a Conjoint Professor in the faculty of medicine at UNSW Sydney. He holds dual Australian and US citizenship.
Michael John Goldacre is an Australian-born British medical doctor and academic. He has been a fellow of Magdalen College since 1985 and was awarded a Title of Distinction as Professor of Public Health at the University of Oxford in 2002. He is a Fellow of the Royal College of Physicians,a Fellow of the Faculty of Public Health, and a Fellow of the Royal Society of Medicine
Sir Gordon William Duff, is a British medical scientist and academic. He was principal of St Hilda's College, Oxford, from 2014 to 2021. He was Lord Florey Professor of Molecular Medicine at the University of Sheffield from 1991 to 2014.
Sir Michael David Rawlins was a British clinical pharmacologist and emeritus professor at the University of Newcastle upon Tyne. During his medical career he chaired several executive agencies including the Committee on Safety of Medicines from 1993 to 1998, followed by the National Institute for Health and Care Excellence (NICE) for 14 years from its formation in 1999 and then the Medicines and Healthcare products Regulatory Agency (MHRA) for six years from 2014. From 2012 to 2014 he was president of the Royal Society of Medicine.
Sir Peter John Ratcliffe, FRS, FMedSci is a British physician-scientist who is trained as a nephrologist. He was a practising clinician at the John Radcliffe Hospital, Oxford and Nuffield Professor of Clinical Medicine and head of the Nuffield Department of Clinical Medicine at the University of Oxford from 2004 to 2016. He has been a Fellow of Magdalen College, Oxford since 2004. In 2016 he became Clinical Research Director at the Francis Crick Institute, retaining a position at Oxford as a member of the Ludwig Institute of Cancer Research and director of the Target Discovery Institute, University of Oxford.
Sir Anthony Herbert Everington, known as Sam Everington, is a GP at a health centre within the Bromley by Bow Centre, in Tower Hamlets, an area of East London.
Dame Moira Katherine Brigid Whyte is a Scottish physician and medical researcher who is the Sir John Crofton Professor of Respiratory Medicine at the University of Edinburgh. She was the Director the Medical Research Council Centre for Inflammation Research and was Vice-Principal and Head of the College of Medicine and Veterinary Medicine at the University of Edinburgh. Whyte is also a trustee of Cancer Research UK.
Sir Stephen Huw Powis is a renal medicine consultant and has been the National Medical Director of NHS England since 2018. Previously he was the chief medical officer at the Royal Free London NHS Foundation Trust. He is also a professor at University College London.
The MRC Weatherall Institute of Molecular Medicine at the University of Oxford is a research institute located at the John Radcliffe Hospital in Oxford. Founded in 1989 by Sir David Weatherall, the institute focuses on furthering our understanding of clinical medicine at a molecular level. It was one of the first institutes of its kind in the world to be dedicated to research in this area.